[DISCLOSURE] HLB Life Science (067630) announced on Sept.19 that it has decided to acquire LSK BioPartners‘ 65,500 shares, worth 5.6 billion won (US$4.98 million). The amount is equivalent to 21.74 percent of the company’s total equity capital.
HLB Life Science now has a 8.76 percent stake in the company, owning 241,800 shares in total.
